The federal Project Grant award R44TR005137 was provided by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, with a total funding of $350,000 and performance period from May 1, 2024 to April 30, 2025. The award supports the development of Cellchorus Inc.'s advanced computational and imaging platform, TIMING, to enable high-resolution, real-time tracking and characterization of individual cell behaviors for cell therapy manufacturing and translational research applications. The key products and services to be delivered under this grant include:
- Developing and optimizing reagents and protocols to identify a suite of cell surface attributes, quantify proliferative capacity, and determine metabolic activity before, during, and after cell-cell interactions.
- Integrating these cell analysis capabilities with Cellchorus' AI-driven software to provide a unified, ready-to-use assay system that can run on commercially available imaging instrumentation.
The goal is to enhance translational research, optimize cell therapy manufacturing, and accelerate the development of novel therapeutic approaches in fields such as oncology, infectious diseases, and immunotherapy by providing sophisticated, AI-powered analytical tools to track and characterize thousands of cells simultaneously with unprecedented detail.
Generated 1/28/25, 6:55 AM